Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 2841-2846, May 15, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wouters, W.
Right arrow Articles by De Coster, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wouters, W.
Right arrow Articles by De Coster, R.

Effects of Liarozole, a New Antitumoral Compound, on Retinoic Acid-induced Inhibition of Cell Growth and on Retinoic Acid Metabolism in MCF-7 Human Breast Cancer Cells

Walter Wouters1, Jacky van Dun, Ann Dillen, Marie-Claire Coene, Willy Cools and Roland De Coster

Departments of Endocrinology and Oncology [W. W., J. v. D., A. D., R. D. C.] and Immunology [M-C. C., W. C.], Janssen Research Foundation, Turnhoutseweg 30, B-2340 Beerse, Belgium

Liarozole is a new imidazole derivative with antitumoral properties. Effects of the compound alone and in combination with all-trans-retinoic acid on proliferation of MCF-7 human breast cancer cells were examined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay.

Following 9 days of drug exposure, MCF-7 cell growth was concentration dependently inhibited by all-trans-retinoic acid (drug concentration resulting in 50% growth inhibition, 2 x 10-8 M), while liarozole at 10-5 M inhibited cell growth by only 35%.

When MCF-7 cells were incubated with a combination of all-trans-retinoic acid and liarozole, the antiproliferative effect of all-trans-retinoic acid was clearly enhanced. This enhancement was dependent on the liarozole concentration and was more than 10-fold. A combination of 10-8 M all-trans-retinoic acid and 10-6 M liarozole resulted in a greater antiproliferative effect than that obtained with 10-7 M all-trans-retinoic acid alone.

When MCF-7 cells were incubated for 4 h with [3H]all-trans-retinoic acid, the radioactivity in the supernatant consisted of unaltered retinoid. However, when cells had been pretreated with 10-6 M all-trans-retinoic acid overnight, they were able to substantially metabolize [3H]all-trans-retinoic acid during a subsequent 4-h incubation. High-performance liquid chromatography analysis of the supernatants revealed that the reaction products consisted mainly of very polar metabolites. Liarozole inhibited the metabolism of all-trans-retinoic acid in MCF-7 cells with 10-5 M liarozole reducing the amount of polar metabolites by 87%.

It is concluded that the enhancement by liarozole of the antiproliferative effects of retinoic acid on MCF-7 human breast cancer cells is probably due to inhibition of retinoic acid metabolism. Further research into these effects in MCF-7 cells as well as in other cancer cell lines will provide more information concerning the exact mechanism of action of liarozole and the use of inhibitors of retinoid metabolism in cancer treatment.

1 To whom requests for reprints should be addressed.

Received 8/ 8/91. Accepted 3/11/92.




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. N. Shelton, I. T. Sandoval, A. Eisinger, S. Chidester, A. Ratnayake, C. M. Ireland, and D. A. Jones
Up-regulation of CYP26A1 in Adenomatous Polyposis Coli-Deficient Vertebrates via a WNT-Dependent Mechanism: Implications for Intestinal Cell Differentiation and Colon Tumor Development.
Cancer Res., August 1, 2006; 66(15): 7571 - 7577.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
C. Liu, R. M. Russell, and X.-D. Wang
Exposing Ferrets to Cigarette Smoke and a Pharmacological Dose of {beta}-Carotene Supplementation Enhance In Vitro Retinoic Acid Catabolism in Lungs via Induction of Cytochrome P450 Enzymes
J. Nutr., January 1, 2003; 133(1): 173 - 179.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. A. White, B. Beckett-Jones, Y.-D. Guo, F. J. Dilworth, J. Bonasoro, G. Jones, and M. Petkovich
cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26)
J. Biol. Chem., July 25, 1997; 272(30): 18538 - 18541.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B.-j. M. van der Leede, C. E. van den Brink, W. W. M. Pijnappel, E. Sonneveld, P. T. van der Saag, and B. van der Burg
Autoinduction of Retinoic Acid Metabolism to Polar Derivatives with Decreased Biological Activity in Retinoic Acid-sensitive, but Not in Retinoic Acid-resistant Human Breast Cancer Cells
J. Biol. Chem., July 18, 1997; 272(29): 17921 - 17928.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. A. White, Y.-D. Guo, K. Baetz, B. Beckett-Jones, J. Bonasoro, K. E. Hsu, F. J. Dilworth, G. Jones, and M. Petkovich
Identification of the Retinoic Acid-inducible All-trans-retinoic Acid 4-Hydroxylase
J. Biol. Chem., November 22, 1996; 271(47): 29922 - 29927.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.